Relamorelin
A Phase I clinical trial showed that relamorelin, compared with placebo, greatly accelerated gastric emptying in patients with diabetic gastroparesis. Subsequently, a Phase II clinical trial demonstrated that relamorelin significantly reduced the frequency of vomiting and improved gastric emptying in patients with diabetic gastroparesis [34]. These results allowed the FDA to grant a rapid appointment for relamorelin for the treatment of diabetic gastroparesis in 2016.
The safety and efficacy of relamorelin in chronic constipation were also assessed. In the Phase II clinical trial, relamorelin significantly reduced symptoms of constipation and accelerated colonic transit in female patients with chronic constipation [35]. Also, the same study showed that relamorelin rapidly increased colonic contractions without any change in irregular fundus contractions. These promising effects of relamorelin in gastrointestinal disorders may lead to a wide range of clinical applications soon [35].